ANVISA announces review of RDC 81/2008 on the import of products subject to health surveillance.

ANVISA RDC review

ANVISA Begins Review of RDC 81/2008: Impacts on Imported Products

QR Group analyzes the effects of the proposal to update the main rule that regulates the import of products subject to health surveillance in Brazil

Regulation of drugs for rare diseases in Brazil advances with new guidelines from ANVISA.

ANVISA regulation

Regulation of Medications for Rare Diseases Advances in Brazil

QR Group analyzes the regulatory impacts of ANVISA’s new guidelines and the challenges for the pharmaceutical industry In recent years, the regulation of medicines for

QR Group technician validating quality assurance system in medical device.

CAPA

QR Group implements Quality Assurance and compliance systems for medical devices

See how QR Group’s Quality Assurance service ensures ISO 13485 standards and compliance with GMP and ANVISA standards QR Group offers a complete quality-assured service,

Avisalegis ANVISA: Tool for regulatory monitoring of medical devices.

ANVISA Petition

How Avisalegis Can Make It Easier to Follow ANVISA Regulations

What is Avisalegis and How Does It Impact the Healthcare Industry? The National Health Surveillance Agency (ANVISA) recently launched Avisalegis, an innovative service that allows

Experts discuss RDC 954/2024 and its impact on drug registration in Brazil.

ANVISA petitioning

RDC 954/2024: Updates to the Simplified Drug Registration Procedure

Key Changes and Impacts for Drug Manufacturers The recent update of RDC 954/2024 brought significant changes to the simplified procedure for registering medicines in Brazil.